STAT Plus: 4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug
The annual Alzheimer’s research meeting known as CTAD was supposed to be a snoozefest this year. That all changed six weeks ago, when Biogen stunned the medical world by bringing an Alzheimer’s drug back from the dead — and vowed to make a detailed scientific case for the decision at the gathering this week.
On Thursday morning, Biogen will give that highly anticipated presentation — livestreamed here — detailing data from two late-stage clinical trials of its drug, known as aducanumab. It will be the highlight of CTAD, short for Clinical Trials on Alzheimer’s Disease.
Continue to STAT Plus to read the full story…
